

HCV Directly Acting Antivirals & RBV

Charts revised October 2019. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; GLP/PIB, Glecaprevir/Pibrentasvir; LED/SOF, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	EBR/GZR	GLP/PIB	LED/SOF	OBV/PTV/r	OBV/PTV/r + DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Hypertension/Heart Failure Agents											
Acebutolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Aliskiren	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ambrisentan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Amiloride	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Azilsartan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Benazepril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bendroflumethiazide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bosentan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bumetanide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Candesartan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Captopril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Chlorothiazide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Chlorthalidone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cilazapril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Clevidipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Clonidine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Doxazosin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Enalapril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Eplerenone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Epoprostenol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Eprosartan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fosinopril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Furosemide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Hydralazine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Hydrochlorothiazide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Iloprost	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Indapamide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Irbesartan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Isradipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ivabradine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lacidipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lercanidipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lisinopril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Losartan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Macitentan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Methyldopa	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Metolazone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Moxonidine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Olmесartan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Perindopril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Prazosin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Quinapril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ramipril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ranolazine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Rilmenidine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Riociguat	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Selexipag	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Sildenafil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Spironolactone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tadalafil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Telmisartan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Torasemide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Trandolapril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Treprostinil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Valsartan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Xipamide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Zofenopril	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦

For personal use only. Not for distribution.

	DCV	EBR/GZR	GLP/PIB	LED/SOF	OBV/PTV/r	OBV/PTV/r + DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Illicit/Recreational											
Amphetamine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cannabis	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cocaine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ecstasy (MDMA)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
GHB (Gamma-hydroxybutyrate)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
LSD (Lysergic acid diethylamide)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mephedrone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Methamphetamine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Phencyclidine (PCP)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Immunosuppressants											
Alemtuzumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Azathioprine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Basiliximab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Brodalumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ciclosporin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Eculizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Etanercept	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fingolimod	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lenalidomide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mycophenolate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pirfenidone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Sirolimus	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tacrolimus	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lipid Lowering Agents											
Atorvastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bezafibrate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ezetimibe	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fenofibrate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fish oils	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fluvastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Gemfibrozil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lovastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pitavastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pravastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Rosuvastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Simvastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
♦	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, Pharmacology Research Labs,
 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised October 2019. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; GLP/PIB, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	EBR/ GZR	GLP/ PIB	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	SMV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Other Drugs											
Acamprosate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acetazolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acitretin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Activated charcoal	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Allopurinol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atomoxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bethahistine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bimatoprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bromocriptine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcitonin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium carbimide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium resonium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbimazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carisoprodol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cilostazol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clomifene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colchicine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colestyramine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Conivaptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclobenzaprine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cytisine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Darbepoetin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Deferiprone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Denosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamfetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dextromethorphan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Disulfiram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Donepezil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dorzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eliglustat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epoetin alfa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etelcalcetide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Febuxostat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Filgrastim	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flibanserin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gadopentetate (gadolinium)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glycerol phenylbutyrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Goserelin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isosorbide mononitrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isotretinoin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lanreotide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levothyroxine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lofexidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lumacaftor/vacaftor	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Magnesium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylphenidate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Minoxidil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Modafinil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naftidrofuryl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nalmefene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nusinersan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orlistat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Penicillamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Protamine sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyridostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sevelamer	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Strontium ranelate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thalidomide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tranexamic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ursodeoxycholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	DCV	EBR/ GZR	GLP/ PIB	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	SMV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Oxytocics											
Ergometrine (ergonovine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mifepristone	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Misoprostol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Parkinsonism Agents											
Benzotropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbidopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pramipexole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rasagiline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ropinirole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
PBC Agents											
Bethidolic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Steroids											
Beclometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betamethasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Budesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ciclesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasol (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamethasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fludrocortisone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flunisolide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylprednisolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednicarbate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednisone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Triamcinolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Urological Agents											
Alfuzosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Finasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirabegron	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Silodosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Solfenacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to symbols

◆	These drugs should not be coadministered
▲	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, Pharmacology Research Labs,
 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.